CN117377496A - 用于降解α-突触核蛋白聚集体的化合物及其用途 - Google Patents

用于降解α-突触核蛋白聚集体的化合物及其用途 Download PDF

Info

Publication number
CN117377496A
CN117377496A CN202180098221.5A CN202180098221A CN117377496A CN 117377496 A CN117377496 A CN 117377496A CN 202180098221 A CN202180098221 A CN 202180098221A CN 117377496 A CN117377496 A CN 117377496A
Authority
CN
China
Prior art keywords
group
alkyl
substituted
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180098221.5A
Other languages
English (en)
Chinese (zh)
Inventor
张明奎
P·坦皮斯特
林易娴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinxu Biotechnology Co ltd
Original Assignee
Xinxu Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinxu Biotechnology Co ltd filed Critical Xinxu Biotechnology Co ltd
Publication of CN117377496A publication Critical patent/CN117377496A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Treating Waste Gases (AREA)
CN202180098221.5A 2021-05-14 2021-05-14 用于降解α-突触核蛋白聚集体的化合物及其用途 Pending CN117377496A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/054167 WO2022238737A1 (en) 2021-05-14 2021-05-14 Compounds for degrading alpha-synuclein aggregates and uses thereof

Publications (1)

Publication Number Publication Date
CN117377496A true CN117377496A (zh) 2024-01-09

Family

ID=76034924

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180098221.5A Pending CN117377496A (zh) 2021-05-14 2021-05-14 用于降解α-突触核蛋白聚集体的化合物及其用途

Country Status (8)

Country Link
EP (1) EP4337259A1 (https=)
JP (1) JP2024517340A (https=)
KR (1) KR20240008335A (https=)
CN (1) CN117377496A (https=)
AU (1) AU2021444937A1 (https=)
CA (1) CA3218573A1 (https=)
TW (1) TW202304516A (https=)
WO (1) WO2022238737A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162452A1 (zh) * 2024-01-29 2025-08-07 思努赛生物科技(上海)有限责任公司 一种识别α-突触核蛋白聚集体的化合物及其用途
CN118845735A (zh) * 2024-06-21 2024-10-29 合肥综合性国家科学中心大健康研究院 金刚烷衍生物在制备离子通道tmem175激动剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300155B2 (en) * 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
ES2965049T3 (es) 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compuestos para la degradación de la proteína tau
TW201946624A (zh) 2018-05-09 2019-12-16 新旭生技股份有限公司 雜芳基化合物及其用途
JP7297053B2 (ja) * 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
PH12022500002A1 (en) * 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof

Also Published As

Publication number Publication date
JP2024517340A (ja) 2024-04-19
CA3218573A1 (en) 2022-11-17
KR20240008335A (ko) 2024-01-18
WO2022238737A1 (en) 2022-11-17
AU2021444937A1 (en) 2023-11-30
TW202304516A (zh) 2023-02-01
EP4337259A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
US8501733B2 (en) Spiroaminodihydrothiazine derivatives
ES2359467T3 (es) Compuestos útiles como inhibidores de proteína quinasas.
JP6851367B2 (ja) Ｉｒａｋ４阻害剤、及びその応用
US12377152B2 (en) Compounds for degrading alpha-synuclein aggregates and uses thereof
AU2003279230A1 (en) AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
JP2023518831A (ja) 変異ｌｒｒｋ２タンパク質分解の選択的モジュレーター及び関連する使用方法
WO2018102751A1 (en) Ire1 small molecule inhibitors
JP5006047B2 (ja) 新規な縮合ピロロカルバゾール
US7671064B2 (en) Fused pyrrolocarbazoles
KR20170087907A (ko) 시르투인 조정제로서의 치환된 가교된 우레아 유사체
CN117377496A (zh) 用于降解α-突触核蛋白聚集体的化合物及其用途
CN114829345A (zh) 酰基磺酰胺化合物及其医药用途
CN109071558B (zh) 取代的三环杂环化合物及其用途
CN114929670A (zh) 治疗化合物和其使用方法
TW202502745A (zh) ４，５－稠和雙環吡咯啶及４，５－稠和雙環吡咯啶－酮化合物
CN112334462A (zh) Oga抑制剂化合物
KR102941832B1 (ko) Cdk9 억제제 및 이의 용도
HK40069557A (en) Compounds for degrading tau protein aggregates and uses thereof
KR20230145397A (ko) 프라더-윌리 증후군의 치료
CN119546607A (zh) Lrrk2抑制剂
HK40069557B (zh) 用於降解tau蛋白聚集体的化合物及其用途
HK1260037B (zh) 取代的三环杂环化合物及其用途
HK1137439B (en) Fused pyrrolocarbazoles and methods for the preparation thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination